Observational and interventional studies provide conflicting evidence regarding optimal blood pressure (BP) control in persons with chronic kidney disease (CKD). Recent publications provide additional information to inform therapeutic decision-making.
INTRODUCTION
Chronic kidney disease (CKD) and hypertension are major health problems in the United States and globally [1] . Treatment of hypertension is one of the few therapeutic interventions for improving outcomes in CKD. The Kidney Disease: Improving Global Outcomes (KDIGO) 2012 clinical practice guideline recommends SBP of as less as 140 mmHg, and DBP of less than 90 mmHg, in nonalbuminuric CKD patients, and less than 130/80 mmHg in those with albuminuria [2] . The 2014 report from the panel appointed to the Eighth Joint National Committee (JNC 8) recommended goal BP less than 140/ 90 mmHg among adults with CKD [3] .
Additional studies examining BP and various clinical outcomes in CKD have been published over the intervening years, but ideal treatment goals are still unclear, as we have contradictory findings from experimental trials and observational studies.
Experimental trials, of course, minimize bias, but this often comes at the expense of generalizability. To apply trial findings to our patients and achieve similar results, our patients must resemble in important respects the trial participants, and we must apply the same interventions and measurements. Observational studies trying to compare treatment approaches have high risk of bias, yet the studied populations and treatments are often more representative of usual practice. In this article, we review recent observational and interventional studies of BP in persons with nondialysis CKD, focusing primarily on the outcomes mortality and incident end-stage renal disease (ESRD), and attempt to reconcile the seemingly contradictory information.
OBSERVATIONAL STUDIES
The observational study designs in this topic vary widely. Administrative cohorts, prospective protocol-driven cohorts, and post-hoc analyses of randomized trials are used. Several studies are limited to those with diagnosed hypertension, or on BP-lowering medications. One study used a more complex cohort design to model hypertensioncontrol strategies [4] . Table 1 summarizes key studies evaluating associations of BP parameters with all-cause mortality. A prospective study of 218 US veterans with nondialysis CKD and mean estimated glomerular filtration rate (eGFR) 38 ml/min/1.73 m 2 , nearly half with diabetes, demonstrated lowest risk of all-cause mortality with baseline SBP of 130-149 mmHg [5] . Higher DBP (!80 mmHg) was associated with lower
Mortality

KEY POINTS
Observational studies consistently reported U-shaped associations between SBP and mortality in those with chronic kidney disease.
SBP less than 110 mmHg is associated with higher risk of cardiovascular and noncardiovascular, nonmalignancy mortality.
Clinical trial data supports intense blood pressure control (<120/80 mmHg) in those with nondiabetic CKD, and more generally in CKD trials more intensive blood pressure lowering results in lower mortality than less intensive therapy.
Application of trial data to clinical practice should include using the trials' blood pressure measurement techniques. [6] .
Mortality is strongly associated with age and previous studies evaluated the relationship of BP, age, and mortality in CKD. An analysis of 21 015 persons aged more than 65 years with hypertension, receiving care through a managed care consortium, evaluated the relationship between SBP and mortality [7] . Over 70% had CKD stage 3A at baseline, and nearly one-third had diabetes. The lowest SBP category ( 120 mmHg) had the highest mortality in all age groups, with 17-41% increased risk compared with those with SBP 131-140 mmHg. Higher SBP (>140 mmHg) was associated with higher mortality only in the 65-70-year-old group, with approximately 40% increased risk. The model adjusted for DBP, which may make the analyses more reflective of pulse pressure (PP) than of SBP per se. Mortality decreased with higher DBP, and did not vary by age group.
An analysis including more than 600 000 US veterans with CKD (mean eGFR 50 ml/min/ 1.73 m 2 ) further investigated the relationship between SBP, DBP, and mortality [8] . In this analysis, U-shaped associations of both SBP and DBP with mortality were observed, with the lowest risk among those with BP 130-159/70-89 mmHg. DBP less than 70 mmHg was also associated with higher mortality risk, in all except those with the highest SBP. A later analysis used a subset of this cohort to compare treatment with different SBP levels [4] . Requirements were set for number of antihypertensives used and increases in antihypertensive therapy to try to isolate the effects of antihypertensive treatment from BP differences related to clinical circumstances and comorbidities. SBP less than 120 mmHg was associated with 70% higher mortality compared with SBP 120-139 mmHg. Another subset of this veteran cohort, of over 300 000 persons with incident CKD, demonstrated that the association of elevated SBP with higher mortality risk was attenuated with older age [9] . These studies generally found no differences with severity of kidney disease. An analysis from the CRIC Study, however, limited to those with eGFR less than 30 ml/min/1.73m 2 found no relationship between SBP and all-cause mortality prior to dialysis initiation [6] .
The fact that elevated BP leads to cardiovascular events is well known, but what explains the relationship between low SBP and DBP and death in CKD? A recent report investigated this by evaluating the association of BP with cause-specific death [10 & ]. A cohort of 45 412 persons with eGFR 15 to less than 60 ml/min/1.73 m 2 receiving at least one antihypertensive medication was created from the electronic health record of a major health system. The ubiquitous U-shaped association of SBP with all-cause mortality was found, with SBP less than 120 and at least 150 mmHg associated with higher mortality. On cause-specific analysis, lower SBP range (<110 mmHg) had higher cardiovascular and noncardiovascular, nonmalignancy mortality. For DBP, the relationship was different. Lower DBP levels (<60mmHg) were associated with higher all-cause and noncardiovascular and nonmalignancy mortality, and higher levels (>90 mmHg) had higher cardiovascular mortality (but lower noncardiovascular and nonmalignancy mortality). These findings help explain the previously observed U-shaped associations, and may have implications for guiding therapy, based on individual risk of various outcomes and avoidance of intensive BP lowering with certain chronic conditions.
End-stage renal disease
In the cohort study of 218 US veterans discussed above, 63 persons progressed to ESRD over 1009 person-years of follow-up [5] . For ESRD, unlike mortality, SBP had linear associations: those with SBP 130-149 mmHg had nearly four times the risk, and at least 150 mmHg had 9 times the risk. An analysis of 16 129 persons with eGFR less than 60 ml/min/ 1.73 m 2 found similar ESRD risk among those with SBP less than 130 and 130-139 mmHg, but progressively increasing risk for higher SBP groups [11] . DBP 90 mmHg and higher was associated with significantly higher risk, but no difference was found among those with lower BP. PP was evaluated as well, but showed no association with outcomes in a model adjusted for SBP [11] . In the analysis of over 300 000 US veterans with incident CKD mentioned previously [9] , 5161 patients progressed to ESRD. A linear association between SBP and ESRD risk was noted, with older age attenuating this relationship. No consistent association between DBP and ESRD was found.
The exposure in most observational studies was baseline BP, but BP changes over time and could influence outcomes. Time-varying SBP was analyzed as the exposure in 3708 persons from the CRIC cohort [12 & ]. ESRD risk more than doubled for SBP 130-139 mmHg, compared with less than 120 mmHg. This was a much more pronounced effect than that seen with baseline SBP alone as the predictor. A secondary analysis of 1099 persons with eGFR less than 30 ml/min/1.73 m 2 taking part in a vitamin supplementation trial found the highest quartiles of SBP and DBP were associated with 20-30% increased risk [13] . A combined outcome of ESRD or death was used in a post-hoc analysis of the RENAAL (Reduction of Endpoints in Noninsulindependent diabetes mellitus with the Angiotensin II Antagonist Losartan) trial data (which tested losartan versus placebo, and set goal BP less than 140/ 90 among all participants), and found direct relationships between both SBP and DBP and the studied outcomes [14] . Post-hoc analysis of the Veterans Affairs Nephropathy in Diabetes (VA NEPHRON D) trial (which tested combined losartan and lisinopril, versus losartan alone, with goal BP in both arms 110-130/less than 80 mmHg) found combined outcome of significant eGFR decline, ESRD, or death to be significantly higher with SBP 140-149 mmHg, compared with 120-129 mmHg [15] . DBP had a U-shaped association with the composite outcome.
Other cardiovascular outcomes
Recently, Sood et al. [16] evaluated the relationship of time-varying BP parameters with significant eGFR decline (!30%) in a cohort with advanced CKD, most of whom with diabetes (mean 16.8 ml/min/ 1.73m
2 ). The investigators found increased eGFR decline at the extremes of SBP (less than 105 or greater than 170 mmHg), and with DBP greater than 90 mmHg. Renal function decline did not vary with PP. The association of SBP, DBP, and PP with atherosclerotic cardiovascular disease (ASCVD) events and heart failure in a subgroup of the CRIC cohort with eGFR less than 30 ml/min/1.73 m 2 found PP alone was associated with significantly higher heart failure risk, whereas higher SBP, DBP, and PP were associated with higher ASCVD risk [17] . The cohort of 300 000 veterans with incident CKD mentioned in previous sections was analyzed for incident coronary heart disease (CHD) and stroke as well, and found linearly increased risk with SBP (attenuated with age), but no trend with DBP [9] . In an analysis of 1099 patients with eGFR less than 30 ml/min/ 1.73 m 2 , the highest quartile of PP, compared with the lowest, was associated with 67% higher risk of cardiovascular events (myocardial infarction, stroke, or extremity amputation) [13] .
Herrington et al. [18 & ] recently published a posthoc analysis of the Study of Heart and Renal Protection (SHARP) investigating the relationship between observed BP parameters and cardiovascular and noncardiovascular outcomes. This analysis, including persons with both nondialysis and dialysisdependent CKD, found that baseline cardiovascular risk influences the association between BP and cardiovascular outcomes. Among those at high cardiovascular risk (defined by clinical history of ASCVD or elevated troponin I), SBP had a U-shaped association with cardiovascular events, but in those at low cardiovascular risk (the remainder of the cohort), lower SBP was associated with lower risk. Analyzing noncardiovascular mortality, the U-shaped association was again observed with SBP among those at high cardiovascular risk, but among those at low-risk noncardiovascular mortality declined with higher SBP [18 & ]. DBP had a U-shaped association with cardiovascular outcomes in both groups, and no trend was observed for the relationship between DBP and noncardiovascular mortality.
INTERVENTIONAL STUDIES
The Systolic Blood Pressure Intervention Trial (SPRINT) compared goal SBP less than 140 mmHg with goal SBP less than 120 mmHg among nondiabetic persons aged 50 or older with increased cardiovascular risk ( . There were no differences, however, in hypotension, syncope, injurious falls, and hyponatremia between the two groups.
A few other trials have tested different BP targets and important outcomes in CKD and have been discussed in several previous reviews. The Modification of Diet in Renal Disease (MDRD) study compared mean arterial pressure (MAP) target less than 92 mmHg with less than 107 mmHg in a cohort with average GFR (iothalamate) 33 ml/min/1.73 m 2 , and no difference was found in ESRD or mortality [22] . A study performed in Japan evaluated 4418 persons aged 65-85 years, of whom 2499 had eGFR less than 60 ml/min/1.73 m 2 [23] . SBP targets of less than 140 mmHg versus less than 160 mmHg were compared, and no differences in the primary renal or cardiovascular outcomes were seen. A small randomized trial of ramipril versus ramipril and felodipine in persons with nondiabetic proteinuric CKD achieved little BP difference in the two arms, and found no difference in ESRD incidence or mortality [24] . The African American Study of Kidney Disease (AASK) trial tested two BP targets (MAP less than 92 versus 102-107 mmHg) among 1094 African Americans with CKD attributed to hypertension [25] . Despite marked BP separation (average of 128/78, versus 141/85), no significant difference was found in ESRD, all-cause mortality, or a composite outcome over 4 years of follow-up.
A recent meta-analysis of randomized controlled trials evaluated the effect of BP control intensity on mortality among persons with CKD stages 3-5 [26 && ]. The authors identified 18 trials testing different BP treatment intensities, including 15 924 persons with CKD and 1293 deaths. The baseline mean SBP was 148 mmHg, which decreased to 132 mmHg in the more intensive arm, compared with 140 mmHg in the less intensive arm. Higher intensity BP control reduced risk of death (odds ratio 0.86, 95% CI 0.76-0.97), and this appeared consistent regardless of intervention type, follow-up time, diabetes, degree of renal dysfunction, and baseline BP [26 && ].
EXPLAINING THE DIFFERENCES BETWEEN OBSERVATIONAL STUDIES AND EXPERIMENTAL TRIALS
Observational studies are fairly consistent on the association of SBP with outcomes in CKD. Persons with SBP much removed from the average in either direction are more likely to die. Persons with SBP higher than the average are more likely to suffer from events that seem likely to be caused by elevated BP, such as myocardial infarction, stroke, or progression to ESRD, and cardiovascular causes of death also appear to explain much of the higher death rate with high SBP. But what is causing deaths in those with lower SBP, and what are the implications for therapeutic decision-making? Two recent analyses, one evaluating cause-specific death [10 & ], and one looking at cardiovascular and noncardiovascular outcomes [18 & ], are relevant to these questions. Lower SBP was associated with higher risk of both cardiovascular and noncardiovascular death in nondialysis CKD [10 & ]. Lower SBP was also found to be associated with higher risk of cardiovascular events only in those with preexisting disease, whereas it was associated with higher risk of noncardiovascular mortality among the entire cohort [18 & ]. Together these results support the idea that lower SBP can be a marker for poor health in CKD, and that reverse causality may be present.
U-shaped or J-shaped associations between physiologic parameters and outcomes are common in CKD epidemiology and to a certain extent these findings are influenced by parameter categorization [27] . It is not surprising that SBP more than 180 mmHg, or DBP less than 50 mmHg, predict poor outcomes. More interesting are the findings nearer the means, where the best course of action may be unclear. For example, should we increase antihypertensive medication dosage or add additional agents in a patient with SBP 130 mmHg, when observational studies suggest higher mortality with SBP less than 120 mmHg, yet SPRINT found reduced mortality with that target? Which wins out, the causal strength of the randomized trial, or the unselected realism of the observational study? That depends, ultimately, on how much the patient, and the treatment, resembles the trial.
The internal validity of SPRINT is undoubted, application of the findings could prevent many deaths [28] , and updated BP clinical guidelines incorporating these important results are anticipated soon. Generalizing to usual clinical practice, however, must be done carefully. The method of BP measurement is particularly salient. A study in 275 predominantly male patients with CKD found measurements using SPRINT methodology (5 min seated rest in a quiet room, followed by three recordings at 1-min intervals) to be 12. The observation that low SBP is associated with higher mortality in CKD may also be related in part to the generally older population included in these observational studies. Many people classified as having CKD (especially those with CKD stage 3A), are elderly, and have significant risk of death from noncardiovascular causes. SPRINT excluded persons with diabetes, and those with at least 1 g total urinary protein per 24 h or urinary albumin at least 600 mg per 24 h, or the analogous spot urine protein to creatinine ratios [19 && ]. Thus, the findings may not apply to many, as nearly 30% of the US CKD population has diabetes [30] , and macroalbuminuria prevalence in the US CKD population is 6% in stage 3 and 39% in stage 4 [31] . Mortality rate in the SPRINT CKD subgroup was 1.6 percent per year with intensive therapy, and 2.2 percent per year with standard therapy. Cardiovascular deaths made up 0.4 deaths per year in the intensive therapy group and 0.7 deaths per year in the standard therapy group [20 && ]. This is much lower than, for example, the death rates of 7.35 percent per year, and 29.3 percent over 3.9 years, in two of the observational cohorts [9,10 & ]. Further, it is important to note that the Action to Control Cardiovascular Risk in Diabetes-Blood Pressure (ACCORD-BP) trial in people with diabetes, which assigned patients to an intensive therapy with a SBP target less than 120 mmHg or a standard therapy with a SBP target less than 140 mmHg, did not find benefit with the intensive BP target [32] .
Cost-effectiveness is an important consideration in instituting an intervention with such wide-ranging applicability as SPRINT. Simulations of applying SPRINT to appropriate patients suggest that cost per quality-adjusted life year gained would be within usually accepted limits [33, 34] .
CONCLUSION
In summary, SPRINT trial data supports intense BP control (less than 120/80 mmHg) in the nondiabetic CKD population, with the caveat that the trial's BP measurement technique must be used. We must consider tradeoffs, however, whenever making decisions with individual patients. The increased medicalization of patients' lives with more frequent physician visits and BP checks, the pill burden, and side effects including AKI (which may have long-term impacts) are among the downsides. Patients must be provided the best available information on risks, benefits, and uncertainties, and their valuations of potential benefits versus certain costs must be taken into account. Additionally, trials are needed to test intensive BP control among patients with diabetic kidney disease and advanced CKD before similar targets can be confidently applied to them. The ultimate goal for clinical science must be to inform clinicians how best to individualize BP targets based on each person's unique clinical circumstances and personal values. Acknowledgements S.D.N. is supported by a grant from the National Institutes of Health (NIDDK-R01DK101500). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. NIH did not have any role in the interpretation of data; writing the report; and the decision to submit the report for publication.
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